In Silico Prediction of Binding Affinities of Hybrid Molecules of Benzothiazole cross-linked with Hydroxamic acid by certain linkers


  • yazen alqaysi pharmaceutical chemistry
  • Shakir M. Alwan Department of Pharmacy, Al-Farabi University College, Baghdad, Iraq
  • Ashour H. Dawood Vise Chancellor Al-Esraa University, Baghdad, Iraq



Benzothiazole, Amino acids, Molecular hybridization, Vorinostat, HDACs inhibitors


New hybrid molecules of Benzothiazole cross-linked with hydroxamic acid through an amino acid or aminoalkanoic acid are suggested. All the synthesized hybrid molecules (2A-E) were subjected to molecular docking to evaluate their binding affinities with histone deacetylase enzyme (HDAC8, PDB ID: 1T69) and recorded lower ΔG (-8.117, -6.322, -8.16, -7.939, - 9.46, respectively)

than Vorinostat (suberoylanilide hydroxamic acid, SAHA), as the reference ligand, which recorded a much less value of -5.375, using the Maestro software (Schrödinger, version 2022-1).  Moreover, compound 2E, which is Benzothiazole-p-amino benzoic acid-hydroxamate has recorded the lowest binding score (-9.460). This may indicate that this compound is the most active hybrid molecule. There were no violations from Lipinski’s rule and all the synthesized hybrid molecules comply with all parameters.  SwissADME server was employed for the in silico molecular docking for prediction of the physicochemical and ADME properties of the investigated compounds.  All hybrid molecules showed low possible passive oral absorption and no penetration into BBB. The hybrid molecules 2B and 2D may be considered as P-gp substrates. SAHA does not inhibit any of the CYP enzymes used in this study, while, the hybrid molecules 2B, 2D and 2E have shown possible inhibitory activities.


- Ruijter, A. J. M., Gennip, A. H., Caron, H. N., Kemp S., & Kuilenburg, A. B. P. (2003). Histone deacetylases (HDACS): Characterization of the classical HDAC family. Biochemical Journal, 370(3), 737–749. DOI:

- Ali, S. A. (2013). Synthesis and preliminary antibacterial study of new 2-mercapto-1, 3- Benzothiazole derivatives with expected biological activity. Al Mustansiriyah Journal of Pharmaceutical Sciences, 13(1), 119–124. DOI:

- Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009). HDAC family: What are the cancer relevant targets? Cancer Letters, 277(1), 8–21. DOI:

- Menta, E., & Palumbo, M. (1997). Novel antineoplastic agents. Expert Opinion on Therapeutic Patents, 7(12), 1401–1426. DOI:

- Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001). Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology, 13(6), 477–483. DOI:

- Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006). Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5(9), 769–784. DOI:

- Shaveta, Mishra, S., & Singh, P. (2016). Hybrid molecules: The privileged scaffolds for various pharmaceuticals. European Journal of Medicinal Chemistry, 124, 500–536. DOI:

- Musso, L., Dallavalle, S., & Zunino, F. (2015). Perspectives in the development of hybrid bifunctional antitumor agents. Biochemical Pharmacology, 96(4), 297–305. DOI:

- Papavassiliou, K. A., & Papavassiliou, A. G. (2013). Histone deacetylases inhibitors: Conjugation to other antitumor pharmacophores provides novel tools for cancer treatment. Expert Opinion on Investigational Drugs, 23(3), 291–294. DOI:

- Sarah Abdul-Razzaq makki, Shakir M Alwan, & Mayada H. Al-Qaissy. (2023). In silico molecular docking, synthesis and preliminary evaluation of antibacterial activity of levofloxacin carboxamides with certain amino acids. Al Mustansiriyah Journal of Pharmaceutical Sciences, 23(1), 22–32. DOI:

- Daina, A., & Zoete, V. (2016). A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. Chem Med. Chem, 11(11), 1117–1121 DOI:

- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4–17. DOI:

- H. Wang, Z.Y. Lim, Y. Zhou, M. Ng, T. Lu, K. Lee, K. Sangthongpitag, K.C. Goh, X. Wang, X. Wub, H.H. Khng, S.K. Goh, W.C. Ong, Z. Bonday, E.T. Sun, Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors, Synthesis, SAR, and in vivo antitumor activity, Bioorg. Med. Chem. Lett. 20 (2010) 3314-3321. DOI:

- J. Jiao, H. Fang, X. Wang, P. Guan, Y. Yuan, W. Xu, Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido) benzamide (HPPB) derivatives as novel histone deacetylase inhibitors, Eur. J. Med. Chem. 44 (2009) 4470-4476. DOI:

- Shakir M. Alwan and Jaafar S. Shia, 2023, In Silico Molecular Docking Study for Prediction of Binding Affinities to Penicillin Binding Proteins and β-Lactamases of Amino Acids-Cephalexin conjugates; Journal of Al-Farabi for Medical Sciences, Vol. 1, No. 1. DOI:




How to Cite

alqaysi, yazen, Shakir M. Alwan, & Ashour H. Dawood. (2024). In Silico Prediction of Binding Affinities of Hybrid Molecules of Benzothiazole cross-linked with Hydroxamic acid by certain linkers. Al Mustansiriyah Journal of Pharmaceutical Sciences, 24(1), 59–67.